Journal article
Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study
Blood cancer journal (New York)
07/23/2026
DOI: 10.1038/s41408-026-01563-2
Abstract
Treatment strategies for relapsed/refractory large B-cell lymphoma (R/R LBCL) have evolved rapidly, yet relationships between therapy selection and outcomes remain poorly defined. The LEO CReWE study evaluated disease characteristics, patterns of care, and outcomes in 1504 patients with R/R LBCL from 2002 to 2022. Of these, 64% received chemoimmunotherapy at second-line (2L). Autologous stem cell transplant (ASCT) and/or chimeric antigen receptor T-cell therapy (CAR-T) were planned at 2L for 984 patients (65%), with 471 (31%) ultimately receiving ASCT and 94 (6%) receiving CAR-T. Complete response (CR) rates at 2L ranged from 24% for lenalidomide-based regimens to 49% for CAR-T; salvage chemotherapy achieved a 44% CR rate overall and 60% among patients who eventually underwent ASCT. Median event-free and overall survival from 2L were 4.3 months and 18.3 months, respectively; survival improved in eras during which CAR-T was available. Patients intended for but unable to receive ASCT or CAR-T experienced poor outcomes comparable to those never intended for curative therapy at 2L. The LEO CReWE study represents the first large-scale depiction of 2L treatment patterns and outcomes for LBCL in the modern era, inclusive of all treatment approaches, and underscores the ongoing need for more effective therapies despite the advent of CAR-T.
Details
- Title: Subtitle
- Treatment patterns and outcomes for second-line therapy in large B-cell lymphoma: results from the LEO CReWE study
- Creators
- Jean L. Koff - Emory UniversityMelissa C. Larson - Mayo Clinic in FloridaJonathon B. Cohen - Emory UniversityIzidore S. Lossos - Sylvester Comprehensive Cancer CenterPeter Martin - Weill Cornell MedicineThomas M. Habermann - Mayo Clinic in ArizonaCarla Casulo - University of RochesterSamuel Yamshon - Cornell UniversityAndrea Lo-RossiAshwini ShewadeConnie Lee BatleviAnthony MasaquelYong MunYucai Wang - Mayo Clinic in ArizonaArushi Khurana - Mayo Clinic in ArizonaGrzegorz S. Nowakowski - Mayo Clinic in ArizonaDai Chihara - The University of Texas MD Anderson Cancer CenterEric Mou - University of IowaUmar Farooq - University of IowaDilan Patel - Washington University in St. LouisAmy Ayers - The University of Texas MD Anderson Cancer CenterTanner W. Reicks - Mayo Clinic in FloridaJames R. Cerhan - Mayo Clinic in FloridaChristopher R. Flowers - The University of Texas MD Anderson Cancer CenterMatthew J. Maurer - Mayo Clinic in ArizonaLoretta J. Nastoupil - The University of Texas MD Anderson Cancer Center
- Resource Type
- Journal article
- Publication Details
- Blood cancer journal (New York)
- DOI
- 10.1038/s41408-026-01563-2
- ISSN
- 2044-5385
- eISSN
- 2044-5385
- Publisher
- Springer Nature
- Language
- English
- Electronic publication date
- 07/23/2026
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9985215015402771
Metrics
1 Record Views